Compare Moderna, Inc. (MRNA) vs Williams Companies Inc (WMB) Price & Performance

Moderna (MRNA) trades at $140.33, down 3.59% on the day, but maintains a bullish technical signal with support at $138 and resistance at $145. Recent positive phase 3 cancer vaccine trial results have driven significant stock appreciation, though financials show declining revenue and negative net income margins. The company has beaten EPS estimates for the last three quarters, with Q3 2026 results pending.

The outlook is mixed; promising clinical developments in oncology offer long-term growth potential, but high valuation multiples and persistent losses pose risks. Analyst consensus is cautious with a $90.08 price target below the current price, reflecting concerns over profitability and competitive pressures in the mRNA therapeutics space.

Williams Companies (WMB) trades at $75.83, up 2.27% with strong analyst support (79% buy ratings) and a $88.14 consensus target. The stock shows bullish technical momentum above key support at $74, supported by recent acquisitions and stable dividend payments. Fundamentals reveal robust profitability with 63.26% gross margins and 25.18% net income margin, though valuation multiples remain elevated with P/E at 30.21.

WMB offers exposure to growing natural gas infrastructure demand with recent $5.5 billion Momentum Midstream acquisition expanding Gulf Coast presence. Risks include regulatory challenges as seen with NJ pipeline permit reversal and elevated debt levels at 52% debt-to-asset ratio. The stock presents growth potential through LNG export expansion but faces execution risks on major projects.